Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock

Herbert Spapen*, Duc Nam Nguyen1, Joris Troubleyn1, Luc Huyghens1 and Johan Schiettecatte2

Abstract

Introduction: Sepsis-associated encephalopathy (SAE) is a diffuse cerebral dysfunction induced by the immunoinflammatory response to infection. Elevated levels of the brain-specific S100B protein are present in many septic patients and reflect the severity of SAE. Adjunctive treatment with drotrecogin alfa (activated) (DrotAA), the human recombinant form of activated protein C, has been shown to improve mortality in patients with severe sepsis-induced organ failure. We studied the effect of DrotAA on S100B levels in patients with acute septic shock who presented with increased baseline values of this biomarker.

Methods: All patients received standard goal-directed resuscitation treatment. Patients with pre-existing or acute neurological disorders were excluded. Based on the Glasgow coma scale (GCS), patients were classified into two groups: GCS ≥ 13 and GCS <13. DrotAA was given as a continuous infusion of 24 μg/kg/h for 96 h. S100B was measured before sedation and the start of DrotAA (0 h) and at 32 h, 64 h and 96 h and at corresponding time points in patients not treated with DrotAA. The lower limit of normal was < 0.5 μg/L.

Results: Fifty-four patients completed the study. S100B was increased in 29 (54%) patients. Twenty-four patients (9 with GCS ≥ 13 and 15 with GCS <13) received DrotAA. S100B levels in DrotAA-treated patients with a GCS <13, though higher at baseline than in untreated subjects (1.21 ± 0.22 μg/L vs. 0.95 ± 0.12 μg/L; P = 0.07), progressively and significantly decreased during infusion (0.96 ± 0.22 μg/L at 32 h, P = 0.3; 0.73 ± 0.12 μg/L at 64 h, P < 0.05; and 0.70 ± 0.13 μg/L at 96 h, P < 0.05 vs. baseline). This patient group had also significantly lower S100B values at 64 h and at 96 h than their untreated counterparts. In the patients with a GCS ≥ 13, S100B levels were not influenced by DrotAA treatment.

Conclusions: S100B-positivity is present in more than half of the patients with septic shock. When increased S100B levels are used as a surrogate for SAE, adjunctive DrotAA treatment seems to beneficially affect the evolution of severe SAE as discriminated by an admission GCS <13.

Introduction

Sepsis-associated encephalopathy (SAE) is a diffuse cerebral dysfunction accompanying an evolving septic state. The pathophysiological alterations underlying SAE are incompletely understood. Basically, there is no direct infection of the brain. Rather, both inflammatory and non-inflammatory processes are involved that induce blood-brain barrier breakdown, cerebrovascular endothelial activation, deregulation of brain metabolic pathways, and brain cell apoptosis [1]. Activated protein C (APC) plays a key role in the preservation of endothelial function and microvascular perfusion during severe sepsis and septic shock. Hence, a dysfunctional protein C pathway is thought to contribute largely to sepsis-induced microvascular and subsequent organ failure. Drotrecogin alfa (activated) (DrotAA), a recombinant human APC, has been shown to improve the microcirculation in vivo. DrotAA also binds directly to specific receptors on endothelial and inflammatory cells, thereby modulating and downregulating inflamma-
hydrocortisone (100 mg loading dose followed by a con-
guration). Cisatracurium (1 to 2 mg/kg/minute) was added
to standard treatment in patients with septic shock.

Materials and methods

The study was approved by the Ethics Committee of our
center and conducted in compliance with the Decla-
ratment aimed to obtain and maintain a mean
tory and apoptotic processes [2]. Adjuvant therapy with
DrotAA has been shown to significantly reduce mortality
in adult patients with severe sepsis [3]. Survival rate was
highest in the most severely ill patients and largely driven
by a more rapid improvement of cardiovascular and
respiratory failure [4].

We have previously demonstrated that levels of the
highly brain-specific protein S100B were increased in low
consciousness SAE, suggesting a possible use for this pro-
tinuous infusion of 0.18 mg/kg/h). Insulin was infused in
al patients to keep glycaemia between 100 and 150 mg/
dL. Patients were not randomized whether or not to
receive DrotAA. Prescription of DrotAA followed
national guidelines but the decision to start the drug was
left at the discretion of the attending physician. When
DrotAA was given, it was administered as a 24-h contin-
ous infusion of 24 μg/kg/minute during four consecutive
days.

In all patients, the Glasgow Coma Scale (GCS) was
assessed before tracheal intubation and start of sedation.
Patients were divided into two groups according to this
baseline GCS being either >13 or <13. A GCS cut-off at
13 was chosen based on the observations of Eidelman et
al. who found a three-fold increase in mortality when the
GCS decreased below 13 [6]. Patients with a GCS <13
underwent a contrast computed brain tomography (Sie-
mens, Sensation 16 Multislice, Forchheim, Germany) to
exclude pre-existing organic or vascular cerebral lesions.
A lumbar puncture was performed in all patients with a
GCS ≤ 8 to exclude brain or meningeal infection.

Blood was drawn from a radial arterial catheter for
measurement of S100B before the start of DrotAA infu-
sion (0 h) and at three distinct time points (32 h, 64 h, and
96 h) thereafter. In patients who did not receive DrotAA,
blood for S100B determination was taken at correspond-
ing time points. All samples were immediately centri-
fuged and aliquoted at -70°C until analysis. S100B was
measured with a monoclonal two-site immunoradio-
metric assay to detect the S100B subunit (Sangtec 100,
Sangtec Medical AB, Dietzenbach, Germany). Test
imprecision between days was <6%, and the lower limit of
normal value was < 0.5 μg/L.

The study was discontinued in patients who developed
significant renal impairment (defined as a two-fold
increase of baseline serum creatinine or the need to start
renal replacement therapy) during the study period.
Patients who survived at least 96 h following enrolment
in the study were evaluated. ICU and hospital mortality
were defined as being alive respectively at ICU dis-
charge and at the end of hospital stay.

SPSS package version 13.0 for Windows (SPSS Inc, Chi-
cago, IL, USA) was used for statistical analysis. Chi-
square and Student’s t-test were used to evaluate differ-
ences in age, gender, mortality and Sequential Organ Fail-
ure Assessment (SOFA) and Acute Physiology and
Chronic Health Evaluation (APACHE) II scores between
patients with GCS ≥ and <13. S100B levels between both
GCS groups were compared using a one-way analysis of
variance for repeated measurements followed by Bonferroni
test for multiple comparisons. Data were expressed
as means ± SD or means ± SEM. Statistical significance
was accepted at P < 0.05.
Results
Fifty-four patients (33 men; 21 women) completed the study protocol. At study entry, 23 had a GCS ≥ 13 and 31 had a GCS <13. S100B levels were elevated in 29 (54%) patients and exceeded 1 μg/L for at least one measurement in 12 (22%) patients. Sixty-five percent of patients with a GCS <13 and 45% of patients with a GCS ≥ 13 had increased S100B levels.

Patients with a GCS <13 had significantly higher APACHE II scores, baseline SOFA scores and higher baseline S100B values than those with a GCS ≥ 13 (Table 1).

Twenty-four patients (9 with GCS ≥ 13 and 15 with GCS <13) received DrotAA. In the group of patients with a GCS <13, those who received DrotAA tended to have higher baseline S100B levels than their untreated counterparts (1.21 ± 0.22 vs. 0.95 ± 0.12 μg/L; P = 0.07). S100B levels progressively decreased during DrotAA infusion in patients with a GCS <13 only (0.96 ± 0.22 μg/L at 32 h; 0.73 ± 0.12 μg/L at 64 h; 0.70 ± 0.13 μg/L at 96 h; all means ± standard error of the mean (SEM); P respectively = 0.3; < 0.05; and < 0.05 compared to baseline). Compared to untreated patients, those who received DrotAA, had significantly lower S100B values at 64 h (1.34 ± 0.12 vs. 0.73 ± 0.12 μg/L; P < 0.05) and at 96 h (1.07 ± 0.13 vs. 0.70 ± 0.13 μg/L; P < 0.05) (Figure 1, upper panel). In contrast, patients with a GCS ≥ 13, had comparable S100B levels within and between groups, that were not affected by DrotAA treatment (Figure 1, lower panel).

Global ICU and in-hospital mortality were high (respectively 59% and 76%) and did not differ between DrotAA-treated and -untreated patients (ICU mortality 62.5% vs. 57%; hospital mortality 75% vs. 77%; both P > 0.05). Mortality was also not different between patients with GCS values above or below 13, regardless DrotAA was given or not (Table 1).

Discussion
Patients with septic shock frequently have alterations in consciousness ranging from mild stupor to coma which cannot be attributed to brain lesions, haemodynamic instability or metabolic disorders [6]. This so-called SAE remains often unnoticed within the clinical spectrum of septic shock that is mostly dominated by life-threatening cardiovascular, respiratory, and renal complications. However, SAE is to be considered as a distinct sepsis-induced organ dysfunction since it is characterized by local expression of pro-inflammatory cytokines in the absence of gross abnormalities of cerebral blood flow or direct infectious involvement of the brain. The pathophysiology of SAE is multifactorial and features cerebrovascular endothelial dysfunction, blood-brain barrier disruption and abnormal neurotransmitter patterns. Main pathological findings include haemorrhagic lesions, microthrombi and abscesses, cyto- and vasogenic oedema, and multifocal necrotizing leukoencephalopathy [1,7,8]. Also, neuronal and microglial apoptosis is detected in brain areas that are involved in the neuroendocrine and behavioural response to stress [9].

Bedside diagnosis and follow-up of SAE are cumbersome. Clinical neurological evaluation, essentially based on GCS assessment, is difficult and rapidly becomes futile when analgesic sedation is started. Daily interruption of sedation is often not feasible during treatment of pneumonia-induced septic shock and may also confound SAE with sedation withdrawal effects. Electroencephalography (EEG) is a more sensitive method to detect brain dysfunction. However, EEG patterns in sepsis are hampered by sedation, show a broad range of interindividual variability, and are difficult to quantify. Also, S100B levels do not correlate with either the GCS or EEG patterns in septic patients [10]. The recording of somatosensory evoked potentials (SEP) provides an elegant and reliable estimation of the severity of SAE [11]. Still, this technique is difficult to use in routine and the relationship between the degree of SEP impairment and corresponding S100B levels in SAE remains to be determined. Cerebrospinal fluid assay and neuroimaging cannot be considered monitoring tools. With the exception of specific situations...
(seizures, focal neurological signs, suspicion of meningeal or cerebral infection), it is also impossible to correctly time these interventions during the course of illness.

S100B is a low-molecular weight, calcium-binding protein secreted by glial and Schwann cells. S100B is released following brain injury of various aetiology. Serum levels of this biomarker correlate positively with the degree of brain injury and neuronal apoptosis and predict the outcome [12-14]. We have previously shown that S100B levels in severe sepsis better reflected the presence and prognosis of low consciousness SAE than the GCS. S100B levels were increased in 42% of patients, exceeding 1 μg/L in 11%. S100B levels between 0.06 and 2 μg/L were typically associated with white matter lesions which are thought to represent the pathological substrate of SAE [5]. In the present study, a higher incidence of S100B elevation was found which probably relates to a higher severity of illness in the patient population studied. The observed high mortality rate is also in line with our earlier findings, indicating a 70% mortality in S100B-positive patients with severe sepsis [5]. It could be argued that the observed high S100B levels might be, at least partially, of extracerebral origin. This is unlikely since common sources of S100B release such as renal failure and surgical tissue injury were either excluded or avoided. Whether serum S100B elevation in sepsis always reflects blood-brain barrier disruption is difficult to prove. Data are conflicting with some authors demonstrating high levels of S100B [15] while others report no evidence of S100B increase [16] in the cerebrospinal fluid. We were unable to measure S100B in the cerebrospinal fluid because lumbar puncture is an absolute contraindication during DrotAAA infusion due to the bleeding risk.

A specific treatment for SAE does not exist. The outcome of SAE is considered to be dependent on prompt and appropriate treatment of the septic process as a whole. Besides control of infection, this also implies management of organ failure, correction of metabolic disturbances, and avoidance of neurotoxic drugs. There is no clinical evidence that adjuvant therapy such as strict glycaemic control with insulin, stress doses of steroids or APC either reduce the incidence or influence the severity and evolution of SAE. Insulin may be neuroprotective as it can prevent hyperglycaemia-induced oxidative stress and apoptotic cell death. However, anticipating insulin effects on SAE is impossible due to the complexity of cerebral glucose metabolism and the high variability in glucose levels between patients. Moreover, intensive insulin therapy does not improve outcome of patients with ischaemic [17] or traumatic [18] brain injury and significantly increases the risk of hypoglycaemia which, by itself, can induce neurocognitive dysfunction [19]. Steroids can decrease systemic inflammation and high doses are known to reduce brain oedema and to restore blood brain barrier function [20]. However, high-dose steroids are associated with higher mortality and increase the risk for secondary infection and hepatorenal dysfunction [21,22]. Stress doses, as given in our patients, have not been shown to reduce serum S100B in septic shock [23].

APC, commercialized as DrotAA, is approved by both the American and European Drug Agencies as an adjunctive treatment of severe sepsis in patients with organ fail-

### Table 1: Patient characteristics and mortality

|                | GCS ≥ 13 | GCS <13 |
|----------------|----------|---------|
| **Gender (M/F; n)** | 12/11    | 21/10   |
| **Age (years; mean ± SD)** | 69 ± 13  | 72 ± 10  |
| **APACHE II score (mean ± SD)** | 17 ± 4 * | 25 ± 7   |
| **Baseline SOFA score (mean ± SD)** | 8 ± 2 *  | 10 ± 3   |
| **Baseline S100B (μg/L; mean ± SEM)** | 0.70 ± 0.08° | 0.96 ± 0.15 |
| **ICU mortality (n; %)†** |          |         |
| DrotAA         | 6 (67)   | 10 (67)  |
| No DrotAA      | 7 (50)   | 9 (56)   |
| **Hospital mortality (n; %)** |          |         |
| DrotAA         | 6 (67)   | 13 (86)  |
| No DrotAA      | 10 (71)  | 12 (75)  |

* P < 0.05, °P = 0.05 as compared to patients with GCS <13
† number and percentage of DrotAA-treated or -untreated patients who died

APACHE: Acute Physiology and Chronic Health Evaluation; DrotAAA: drotrecogin alfa (activated); F: female; ICU: intensive care unit; M: male; SOFA: Sequential Organ Failure Assessment
ure and/or at high risk of death. Independent of its clinically apparent anticoagulant activity, APC directly interferes at the interface between the (micro)vascular endothelium and the innate immune response. The binding of APC on endothelial and inflammatory cell receptors exerts pleiotropic in vitro intra- and intercellular effects, altering gene expression profiles, inhibiting apoptosis and down-regulating inflammation. As a result, APC preserves, protects and probably even restores endothelial function which may attenuate ongoing and prevent further organ damage [24]. This concept is corroborated by the proven benefit of adjunctive DrotAA treatment on cardiovascular, respiratory and haematological disorders in severe clinical sepsis [4]. The effect of the drug on sepsis-induced renal and cerebral dysfunction, however, is less evident, mainly because sensitive parameters for objective evaluation of these organ systems are lacking.

The cerebral effects of APC become progressively elucidated. In mice, APC crosses the blood-brain barrier via binding on the endothelial protein C receptor, acts directly on neurons, microglial cells, microvessels and motor neurons [25], and protects stressed brain endothelial cells from hypoxic/ischaemic damage [26]. In a rat model of periventricular leukomalacia, an injury that mimics the pathophysiological findings of SAE, treatment with APC was associated with less endotoxin-induced white matter and myelination deficits. This protective effect was associated with a decrease in neuronal apoptosis and reduced local expression of pro-inflammatory cytokines [27]. Finally, APC has neuroprotective activity in human ischaemic brain [28] by regulating cytosolic Ca²⁺ flux and blocking apoptosis in brain endothelial cells [29]. The present study suggests that APC may attenuate SAE but only in patients with clinically more severe neurological dysfunction. This is in line with previous observations showing that APC tends to be more effective in the most critically ill patients.

Our study has important limitations. Though representing a rather homogenous septic shock population, the number of patients is small. This precludes a reliable assessment of any possible impact of structural components of the sepsis resuscitation protocol (amount and type of fluid, catecholamine use, sedation level, glycaemic control, nutritional status) on the evolution of SAE. Patients were also studied for a short period of time and S100B behaviour after DrotAA treatment had been stopped is unknown. The decrease in S100B in DrotAA-treated patients was not paralleled by a decrease in mortality. This suggests that the presumed attenuation of SAE does not play a preponderant role in septic shock survival.

Conclusions
This study is the first to show a probable beneficial effect of APC on the evolution of severe SAE, defined as an admission GCS <13, in clinical septic shock. The usefulness of S100B as a serum biomarker for bedside diagnosis of SAE and its role in the evaluation of specific treatment effects on this particular condition merits further investigation. Our findings also call for more comprehensive experimental and clinical research to clarify the relationship between S100B protein behaviour and the extent of concomitant electrophysiological, cerebrovascular, and neurohormonal alterations in severe clinical sepsis and septic shock.

Key messages
- The S100B peptide is a potential serum biomarker for bedside diagnosis and follow-up of sepsis-associated encephalopathy.
- Adjunctive treatment with activated protein C may attenuate the encephalopathy that accompanies septic shock. However, the beneficial effect is only present in more severe encephalopathy and does not affect mortality.

Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; APC: activated protein C; DrotAA: Drotrecogin alfa (activated); EEG: electroencephalography; GCS: Glasgow Coma Scale; ICU: intensive care unit; SAE: sepsis-associated encephalopathy; SEP: somatosensory evoked potentials; SOFA: Sequential Organ Failure Assessment.

Competing interests
HS has been an investigator for studies sponsored by Eli-Lilly, the manufacturer of drotrecogin alfa (activated), and has received an honorarium from Eli-Lilly for serving as a member of local Advisory Boards. All other authors declare that they have no competing interests.

Authors’ contributions
HS and DNN conceived the study, and analyzed, interpreted and integrated the data. They also elaborated the manuscript. JT and LH performed and supervised the enrolment of patients in the study. JS performed the S100B assay. All authors read and approved the final version of the manuscript.

Author Details
1Intensive Care Department, University Hospital, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium and 2Department of Immunology, University Hospital, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium

Received: 18 January 2010 Revised: 8 March 2010 Accepted: 7 April 2010 Published: 7 April 2010

References
1. Sharshar T, Annane D, de la Grandmaison GL, Brouland JP, Hopkinson NS, Françoise G: The neuropathology of septic shock. Brain Pathol 2004, 14:21-33.
2. Levi M, Poll T van der: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007, 11:53.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Hetterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 345:699-709.
4. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Johnson G III, Bernard GR: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2005, 31:384-400.

5. Nguyen DN, Spapen H, Su F, Schiettecatte J, Shi L, Hachimi-Idrissi S, Huyghens L: Elevated serum levels of S-100β protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit Care Med 2004, 32:1746-1747.

6. Edelman LA, Putteman D, Putterman C, Putterman D, Jones T, Towner RA, Castro-Faria-Neto HC: Sepsis-associated encephalopathy: a magnetic resonance imaging and spectroscopy study. J Cereb Blood Flow Metab 2010, 30:440-448.

7. Sharshar T, Gray F, de la Grandmaison GL, Hopkinson NS, Ross E, Nguyen DN, Spapen H, Su F, Schiettecatte J, Shi L, Hachimi-Idrissi S, Carlier R, Bernard F, Guidoux C, Brouland JF, Nardi O, de la Grandmaison GL, Abdo J, Menon D, Annane D: Brain lesions in septic shock: a magnetic resonance imaging study. Intensive Care Med 2007, 33:798-806.

8. Bozza FA, Garteiser P, Oliveira MF, Doblas S, Stanford R, Saunders D, Jones T, Towner RA, Castro-Faria-Neto HC: Sepsis-associated encephalopathy: a magnetic resonance imaging and spectroscopy study. J Cereb Blood Flow Metab 2010, 30:1136-1139.

9. Sharshar T, Gray F, de la Grandmaison GL, Hopkins NS, Ross E, Delandrie A, Orlikowski D, Raphael JC, Gajdos P, Annane D: Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003, 362:1799-1805.

10. Piazza O, Russo E, Cotena S, Esposito G, Tufano R: Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis. Br J Anaesth 2007, 99:518-521.

11. Zauler C, Genda A, Kramer L, Funk GC, Bauer E, Schenk P, Ratheiser K, Madi C: Impaired subcortical and cortical sensory evoked potential pathways in septic patients. Crit Care Med 2002, 30:1136-1139.

12. Pleines VE, Morganti-Kossmann MC, Rancan M, Jollie N, Tzent O, Kossmann T: S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001, 18:491-498.

13. Herrmann M, Vos P, Wunderlich MT, de Brujin CH, Lamers KJ: Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and gliarial fibrillary acidic protein. Stroke 2000, 31:2670-2677.

14. Georgadis D, Berger A, Kowatschew E, Lautenschlager C, Boerner A, Lindner A, Schulte-Matter W, Zerkowski HR, Zierer S, Deufel T: Predictive value of S-100B and neuron-specific enolase serum levels for adverse neurologic outcome after cardiac surgery. J Thorac Cardiovasc Surg 2000, 119:138-147.

15. Hamed SA, Hamed EA, Abella MM: Septic encephalopathy: relationship to serum and cerebrospinal fluid levels of adhesion molecules, lipid peroxides and S-100B protein. Neuropediatrics 2009, 40:66-72.

16. Piazza O, Cotena S, De Robertis E, Casanci F, Tufano R: Sepsis associated encephalopathy studied by MRI and cerebral spinal fluid S100B measurement. Neurochem Res 2009, 34:1289-1292.

17. Bruno A, Kent TA, Coull BM, Shankar RR, Saha C, Becker KJ, Kissela BM, Williams LS: Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 2008, 39:3094-3098.

18. Blotta C, Caramia R, Genni J, Paoloni FP, Dornizati A, Cuzzzone V, Santoro A, Rosa G: Intensive insulin therapy after severe traumatic brain injury: a randomized clinical trial. Neurocrit Care 2008, 9:159-166.

19. Dunning T, Heulev I, van den Dickmann A, Volkert T, Wempe C, Reinholt J, Lohmann H, Freise H, Elger B: Hypoglycaemia aggravates critical illness induced neurocognitive dysfunction. Diabetes Care 2010, 33:639-644.

20. Fitch MT, Bieck D: Drug Insight: steroids in CNS infections - diseases new indications for an old therapy. Nat Clin Pract Neurol 2008, 4:97-104.

21. Cronin L, Cook DI, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430-1439.

22. Stratman GJ, Fisher CJ Jr, Bone RC, Clemmer TP, Metz CA: Deterrent effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1995, 23:191-195.

23. Mussack T, Biegele J, Schelleng G, Biberthaler P, Jochum M: Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock. Clin Chem Lab Med 2005, 43:259-268.

24. O'Brien LA, Gupta A, Grinnell BW: Activated protein C and sepsis. Front Biosci 2006, 11:676-698.

25. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thyagarajan M, Deane F, Fernandez JA, Lane S, Zlocovich AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic K, Cleveland DW, Zlokovic BV: Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009, 119:3437-3449.

26. Shibata M, Kumar SR, Apar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV: Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001, 103:1799-1805.

27. Yesilirmak DC, Kumral A, Baskin H, Ergur BU, Akyan S, Genc S, Genc K, Yilmaz D, Tugyan K, Gray O, Duman N, Odak H: Activated protein C reduces endotoxin-induced white matter injury in the developing rat brain. Brain Research 2007, 1164:14-23.

28. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p38-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003, 9:338-342.

29. Domotor E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV: Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. J Biol 2003, 101:4797-4801.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit